Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Not applicable

Safety and Performance of a Pulsed Field Device for Global Mapping and Ablation of the Left Atrium for the Treatment of Atrial Fibrillation

NCT05164107 · tracked via the Priya Life Science Czechia tracker
Phase
Not applicable
Started
2021-12-08
Last updated
2026-01-30

Condition(s) studied

Atrial Fibrillation

Investigational drug(s) / intervention(s)

Globe Mapping and Pulsed Field Ablation System (Globe PF System)

Globe Mapping and Pulsed Field Ablation System (Globe PF System): During the procedure, the Globe Catheter will be delivered via standard femoral vein access and transseptal puncture. Anatomical and electrophysiological mapping of the left atrium (LA) will be followed by pulsed field ablation (PFA) to achieve pulmonary vein isolation (PVI). Additional PFA or radiofrequency (RF) ablation lesions may be created as deemed appropriate by the Investigator. Intracardiac electrogram mapping with the Globe PF System will be used to confirm PVI.

Study summary

The purpose of this study is to provide clinical data pertaining to the safety and performance of the Globe Mapping and Pulsed Field Ablation System for treating subjects with atrial fibrillation (AF).

Eligibility

Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Key Inclusion Criteria: 1. Subjects planned for an AF catheter ablation procedure, with a documented history of AF. 1. Diagnosis must be confirmed within 12 months before enrollment. 2. (Repeat ablations) Patient had 1 previous PVI procedure with cryoablation, radiofrequency ablation or pulsed field ablation 2. Subjects between 18 and 75 years of age, inclusive Key Exclusion Criteria: 1. Patients who have contraindications to open heart surgery 2. Patients from an Intensive Care Unit 3. Patients with active systemic infection (sepsis) 4. Patients who have had previous ablation in the left or right atrium 5. Patients who are post-heart transplant or who are awaiting cardiac transplantation or other cardiac surgery 6. Patients with cardiac implants that may interfere with device delivery or positioning (e.g. atrial septal defect closure device, left atrial appendage occluder) 7. Patients with mitral valve prolapse or other heart valve abnormalities excepting mild to moderate mitral regurgitation 8. Patients with New York Heart Association Class III or IV heart failure 9. History of a documented thromboembolic event, including stroke or transient ischemic attack (TIA) 10. Bleeding disorder history 11. Patients with a known sensitivity to anesthesia or neuromuscular block agent 12. Currently undergoing long-term treatment with steroids, not including intermittent use of inhaled steroids for respiratory disease 13. Myocardial infarction within the last three months 14. Atrioventricular (AV) block II° or III° 15. Left ventricular ejection fraction (LVEF) of less than 35% 16. Unstable angina

Primary outcome measure(s)

  • Rate of subjects presenting with primary safety events which are device- or procedure-related — up to 3-month visit

Trial sites (1)

FacilityCityRegionStatus
Motol and Homolka University Hospital Prague Czechia Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT05164107 on ClinicalTrials.gov ↗ ← All trials in Czechia